STERIS raised its profit target. Tariff refunds do most of the work.

STERIS raised its annual adjusted earnings forecast after a strong quarter in Life Sciences. Tariff refunds account for most of the increase, while the company's overall sales-growth and cash-flow targets remain unchanged.

The infection-prevention company now expects adjusted profit of $11.35 to $11.55 a share for the year ending March 31, 2027. That is 25 cents more at each end of the range. Management says 18 cents of the increase comes from tariff refunds already received.

There is real operating growth alongside that benefit. Second-quarter revenue rose about 9% to $1.59 billion, and net income attributable to shareholders increased to $213.7 million from $191.9 million. But the improvement varies across the business, and a large planned acquisition will change its funding needs.

The two profit forecasts tell different stories

Research by Ticker Byline shows that STERIS's earnings forecast under standard U.S. accounting rules stayed at $8.92 to $9.12 a share when we compared the November release with August's original outlook. Only the adjusted profit range moved higher.

Adjusted earnings remove costs such as acquired-asset amortization and restructuring. In the two releases' forecast reconciliations, the restructuring adjustment rose by 21 cents a share. Tariff refunds remain included in both the standard and adjusted profit measures.

STERIS received about $24 million of tariff-related refunds and interest in the first half, including roughly $20 million in the second quarter. Those recoveries improve this year's earnings without requiring additional customer sales.

Life Sciences gets a higher target; sterilization gets a lower one

Life Sciences, which supplies equipment, consumables and services to laboratories and pharmaceutical customers, was the quarter's strongest performer. Sales rose nearly 18%, helped by a sharp increase in equipment revenue. Management raised the segment's annual growth forecast, excluding currency movements, acquisitions and divestitures, to 9% to 10% from 6% to 7%.

Applied Sterilization Technologies went the other way on expectations. Its sales grew about 5%, but the annual growth target on the same currency-and-acquisition basis fell to 6% to 7% from 7% to 8%. Higher prices supported earnings, while inflation and depreciation absorbed part of the benefit.

Company-wide revenue is still expected to grow 7% to 8%. Chief executive Dan Carestio described underlying performance as stable. The higher earnings target therefore combines stronger Life Sciences performance with a refund benefit and slower expected growth in sterilization services.

Cash matters ahead of the Xodus purchase

First-half operating cash flow fell to $656.1 million from $707.8 million. Building inventory absorbed cash, helping explain why cash flow weakened even as earnings grew. Free cash flow after capital spending was $492.5 million, down from $527.7 million. The annual free-cash-flow target remains about $800 million.

STERIS is also preparing to buy surgical-products supplier Xodus Medical for $2.1 billion in cash, with a possible additional payment of up to $150 million tied to performance. The pending purchase is excluded from the current earnings forecast; management plans to update the outlook after closing.

The company expects to use about $2 billion of new debt plus existing cash. A new $500 million delayed-draw loan commitment replaces part of its bridge financing, reducing the remaining bridge commitment to $1.5 billion. The new loan can be drawn only when the acquisition closes.

With the refunds already recognized, the next operating test is whether Life Sciences can sustain its stronger pace and the sterilization business can meet its revised target. The STERIS company profile tracks those forecasts, the separate restructuring plans and the acquisition financing.